Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea · Delayed Price · Currency is KRW 28,600
-500 (-1.72%)
Apr 2, 2026, 3:30 PM KST
Daihan Pharmaceutical Revenue
In the year 2025, Daihan Pharmaceutical had annual revenue of 208.61B KRW with 2.16% growth. Daihan Pharmaceutical had revenue of 51.06B in the quarter ending December 31, 2025, a decrease of -0.75%.
Revenue
208.61B
Revenue Growth
+2.16%
P/S Ratio
0.82
Revenue / Employee
377.24M
Employees
553
Market Cap
171.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 208.61B | 4.42B | 2.16% |
| Dec 31, 2024 | 204.19B | 8.28B | 4.23% |
| Dec 31, 2023 | 195.91B | 11.64B | 6.32% |
| Dec 31, 2022 | 184.27B | 12.80B | 7.47% |
| Dec 31, 2021 | 171.46B | 5.38B | 3.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dongwha Pharm.Co.,Ltd | 496.39B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| Kyongbo Pharmaceutical | 264.10B |
| JW Lifescience | 257.83B |
| Whan In Pharm | 255.21B |
| Samil Pharmaceutical Co.,Ltd | 215.04B |
| REYON Pharmaceutical | 149.34B |
| Hana Pharm | 139.33B |